AC Immune (ACIU) investor relations material

Strategic focus and pipeline overview

• Emphasis on precision prevention and targeted therapeutics for neurodegenerative diseases, leveraging active immunotherapies and small molecule programs targeting toxic proteins.

• Differentiated technology platforms validated through multiple clinical candidates and partnerships with major pharmaceutical companies.

• Pipeline includes candidates for Alzheimer's and Parkinson's diseases, with several programs in Phase 1 to Phase 3 trials and FDA Fast Track designations.

• Over CHF 4.3 billion in potential milestone payments from strategic partnerships.

• Cash reserves of CHF 74.8 million, funding operations into Q4 2027.

Clinical development highlights

• ACI-7104, an active immunotherapy for early-stage Parkinson's, demonstrated safety, robust antibody response, and stabilization of disease biomarkers in Phase 2 interim results.

• ACI-35 is the only active immunotherapy in a prevention study for pre-symptomatic Alzheimer's, with a Phase 2 trial targeting tau pathology.

• ACI-24, targeting Abeta in Alzheimer's and Down syndrome, showed significant plaque reduction in preclinical models and dose-dependent immune response in clinical studies.

• NLRP3 inhibitor ACI-19764 demonstrated strong brain penetration, safety, and efficacy in preclinical neuroinflammation and neurodegeneration models; Phase 1 ongoing.

• Morphomer small molecules and PET tracers are advancing for both therapeutic and diagnostic applications in neurodegenerative diseases.

Key milestones and next steps

• Multiple clinical readouts and regulatory submissions expected in 2026, including Phase 2 and Phase 1 trial results for key programs.

• ACI-7104 to advance towards registration, with data supporting disease modification and slowed motor deterioration in Parkinson's.

• Ongoing business development to optimize value and risk, with significant upside from unpartnered programs and technology platforms.

• Continued focus on biomarker-driven development and global access through cost-effective, long-lasting therapies.